0RFI Stock Overview
Engages in the research and development of Bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
BRAIN Biotech AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €3.48 |
52 Week High | €4.47 |
52 Week Low | €1.47 |
Beta | 1.2 |
1 Month Change | 5.14% |
3 Month Change | 57.47% |
1 Year Change | n/a |
3 Year Change | -61.75% |
5 Year Change | -69.83% |
Change since IPO | -62.98% |
Recent News & Updates
Recent updates
Shareholder Returns
0RFI | GB Chemicals | GB Market | |
---|---|---|---|
7D | 2.1% | 2.0% | 0.5% |
1Y | n/a | -24.9% | 2.7% |
Return vs Industry: Insufficient data to determine how 0RFI performed against the UK Chemicals industry.
Return vs Market: Insufficient data to determine how 0RFI performed against the UK Market.
Price Volatility
0RFI volatility | |
---|---|
0RFI Average Weekly Movement | 17.3% |
Chemicals Industry Average Movement | 6.0% |
Market Average Movement | 4.7% |
10% most volatile stocks in GB Market | 10.5% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0RFI's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0RFI's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | 319 | Aryan Moelker | www.brain-biotech.com |
BRAIN Biotech AG engages in the research and development of Bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. It operates in three segments: BioProducts, BioScience, and BioIncubator. The company offers enzymes and biocatalysts to produce food and beverages, wound care preparations or lubricants, and production of starch and bioethanol; and microorganisms as the functional biomass for optimized industrial production processes, recycling of the greenhouse gas CO2 as an industrial raw material, and urban and green mining for extraction of precious and rare earth metals.
BRAIN Biotech AG Fundamentals Summary
0RFI fundamental statistics | |
---|---|
Market cap | €75.16m |
Earnings (TTM) | -€8.77m |
Revenue (TTM) | €56.26m |
1.3x
P/S Ratio-8.6x
P/E RatioIs 0RFI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0RFI income statement (TTM) | |
---|---|
Revenue | €56.26m |
Cost of Revenue | €24.98m |
Gross Profit | €31.29m |
Other Expenses | €40.06m |
Earnings | -€8.77m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Jan 15, 2025
Earnings per share (EPS) | -0.40 |
Gross Margin | 55.61% |
Net Profit Margin | -15.59% |
Debt/Equity Ratio | 0% |
How did 0RFI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/27 19:49 |
End of Day Share Price | 2024/12/27 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BRAIN Biotech AG is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Volker Bosse | Baader Helvea Equity Research |
Thomas Meyer | Baader Helvea Equity Research |
Laura Lopez Pineda | Baader Helvea Equity Research |